Condition: Solid Tumor, Adult · Squamous Cell Carcinoma of Head and Neck · Colorectal Adenocarcinoma · Sponsor: TyrNovo Ltd.
This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX® (cetuximab) in adults with recurrent and/or metastatic solid tumors.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| California Cancer Associates for Research and Excellence | Encinitas, California, United States | — |
| The Angeles Clinic and Research Institute | Los Angeles, California, United States | — |
| UCSD Moores Cancer Center | San Diego, California, United States | — |
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | — |
| The University of Chicago and Biological Sciences | Chicago, Illinois, United States | — |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | — |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | — |
| Hadassah University Medical Center | Jerusalem, Israel | — |
| Rabin Medical Center | Petah Tikva, Israel | — |
| Sourasky Medical Center | Tel Aviv, Israel | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04474470